1/30
08:30 am
mens
Jyong Biotech Subsidiary Announces Phase II Clinical Data on Cholesterol and LDH Indicators for MCS-8 (PCP), Indicating Potential in Prostate Cancer Prevention and Metabolic Value
Medium
Report
Jyong Biotech Subsidiary Announces Phase II Clinical Data on Cholesterol and LDH Indicators for MCS-8 (PCP), Indicating Potential in Prostate Cancer Prevention and Metabolic Value
1/24
05:09 am
mens
Jyong Biotech (NASDAQ:MENS) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Jyong Biotech (NASDAQ:MENS) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
12/19
09:00 am
mens
Jyong Biotech Responds to Share Price and Volume Movement
Low
Report
Jyong Biotech Responds to Share Price and Volume Movement
12/4
08:30 am
mens
Jyong Biotech Expands Regional Partnerships, Signs MOU with a Vietnam Pharmaceutical Distributor for MCS-2 Market Entry
Low
Report
Jyong Biotech Expands Regional Partnerships, Signs MOU with a Vietnam Pharmaceutical Distributor for MCS-2 Market Entry
11/24
08:30 am
mens
Jyong Biotech Ltd. Signs Non-Binding Letter of Intent with Leading South Korean Pharmaceutical Company to Evaluate In-Licensing of Plant-Derived MCS Drugs
High
Report
Jyong Biotech Ltd. Signs Non-Binding Letter of Intent with Leading South Korean Pharmaceutical Company to Evaluate In-Licensing of Plant-Derived MCS Drugs
11/20
08:30 am
mens
Jyong Biotech Announces Completion of Primary Endpoint Statistical Analysis for Phase II Clinical Trial of MCS-8 With Positive Outcomes
Medium
Report
Jyong Biotech Announces Completion of Primary Endpoint Statistical Analysis for Phase II Clinical Trial of MCS-8 With Positive Outcomes